SCIENION's sciFLEXARRAYER used for the production of Anagnostics' integrated sepsis testing products

(PresseBox) (Dortmund/St. Valentin, ) SCIENION AG and Anagnostics Bioanalysis GmbH today announced that Anagnostics is using Scienion's sciFLEXARRAYER for the production of Anagnostics new product line focusing on integrated sepsis testing, based on DNA and protein based multiplex assays.

Anagnostics is specialized in developing systems and tests for multiplex diagnostics and has developed its proprietary hybcell technology. Anagnostics' hybcell is the world's first DNA or protein microarray based on the use of cylinders instead of slides. The microarray is spotted on the outside of a cylinder, fitting in a hollow cylinder, serving as sample container. These hybcells are automatically processed by the laboratory device - the hyborgs, Anagnostics' fully integrated and automated single device system for multiplexed diagnostics. Minimum hands-on time, simple usage and fast and comprehensive results make this system perfectly suitable for (clinical) routine diagnostics.

Especially in sepsis diagnostics a fast and reliable technology is needed in clinics. The complexity of the disease demands comprehensive answers which only multiplexed technologies can deliver in due time.

"The sciFLEXARRAYER proved to be the best dispensing device to print our hybcells, be it for DNA or protein based tests", says Christoph Reschreiter, CEO of Anagnostics Bioanalysis GmbH. "We produce ready to use microarrays for our customers and precision and reproducibility have been key criteria when we decided to work with this Scienion dispenser." For printing the cylindrical microarrays Anagnostics has developed a spotting adapter. hybcells have been developed for drugs of abuse screening, companion diagnostics and for integrated sepsis testing. Integrated sepsis testing combines the concept of molecular pathogen and resistances detection based on DNA with the monitoring of a panel of inflammation markers to survey the patient's immune status.

Holger Eickhoff, CEO of SCIENION AG, comments: "We have experienced Anagnostics as a very reliable partner with excellent people and a superb technology. Facing a dynamic development of next generation diagnostic products, Anagnostics with its novel hybcell technology does make an obvious contribution in this development. We are very pleased that hybcells are being produced with our sciFLEXARRAYER and once more we have demonstrated the versatility of our devices. Scienion enables the dispensing of any kind of content to any kind of surface such as these novel cylindrical microarrays."

About Anagnostics Bioanalysis GmbH

Anagnostics focuses on developing systems and tests for clinical in-vitro-diagnostics. Anagnostics' aim is to provide solutions for unmet clinical needs especially in the field of drugs of abuse screening, companion diagnostics and diagnostics in the context of sepsis. The company specializes in sophisticated protein and DNA assays and tests.

Anagnostics' products contribute to a better living by boosting life sciences and improving health care and therapeutic concepts.

Anagnostics' vision is to establish hybcell technology, a breakthrough development in multiplexed diagnostics in clinical laboratories all over the world.


Scienion AG
Otto-Hahn-Straße 15
D-44227 Dortmund
Social Media